Recent Finacing
Recent Raise
HERVolution Therapeutics engineers immunotherapies targeting human endogenous retroviruses using redesigned antigens delivered via adenoviral vectors, virus-like particles, and mRNA, advancing dual-vector and mRNA prime-boost candidates toward clinical trials.
